News NICE approves neuroblastoma immunotherapy drug for NHS use NICE has approved a drug to treat children with high-risk neuroblastoma within the NHS in England and Wales.
News Taking lenient stance, NICE backs neuroblastoma drug Body makes special case due to rarity of the disease
R&D Immune mediation, B-cell depletion, and female leadership – ... In a new pharmaphorum podcast, Aoife Brennan, CEO of Climb Bio, discusses the treatment of immune-mediated diseases.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
